rosiglitazone - Compound Summary (CID 77999) Also known as: Avandia, Rosiglizole, Brl-49653, 122320-73-4, Brl 49653, Rosigliazone maleate, rosiglitazona, rosiglitazonum, Rosigilitazone Molecular Formula: C18H19N3O3S Molecular Weight: 357.42676 InChIKey: YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl).
Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPAR³. Rosiglitazone is a selective ligand of PPAR³, and has no PPAR±-binding action.
Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFºB) levels fall and inhibitor (IºB) levels increase in patients on rosiglitazone.
Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway. From: DrugBank | ||
Show subcontent titlesTable of Contents Target Enzyme Transporter Action General Function Specific Function Gene Name GenBank Gene GenBank Protein References | ||
Identification Related Records Use and Manufacturing Pharmacology Biomedical Effects and Toxicity Safety and Handling Environmental Fate and Exposure Potential Exposure Standards and Regulations Monitoring and Analysis Methods Literature Patents Biomolecular Interactions and Pathways Biological Test Results Classification Chemical and Physical Properties | ||
